<DOC>
	<DOCNO>NCT02906150</DOCNO>
	<brief_summary>Thymosin alpha 1 plus maintenance therapy Standard Care ( SoC ) chemotherapy plus cisplatin ( carboplatin ) patient metastatic Non-Small Cell Lung Cancer ( NSCLC ) , EGFR wild type</brief_summary>
	<brief_title>Thymosin Alpha 1 Plus Maintenance Therapy With Standard Care ( SoC ) Patients With Metastatic Non-Small Cell Lung Cancer ( NSCLC ) , EGFR Wild Type</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Age 18 year old Histological cytological confirmation NSCLC ( may initial diagnosis NSCLC subsequent biopsy ) . Only patient available tissue sample may include study ( see major detail section 8 minimum sample characteristic ) Activating mutation EGFR diagnosis Stage IIIB ( cytologically proven pleural effusion pericardial effusion ) metastatic NSCLC , amenable curative surgery radiotherapy Measurable disease Response Evaluation Criteria Solid Tumours ( RECIST ) lesion previously irradiate nonmeasurable disease ( non measurable disease Phase I ) Eastern Cooperative Oncology Group performance status ( ECOGPS ) 02 Absolute neutrophil count ( ANC ) &gt; 1.5 x 109/liter ( L ) platelets &gt; 100 x 109/L Bilirubin level either normal &lt; 1.5 x ULN AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 x ULN ( â‰¤ 5 x ULN liver metastasis present ) Serum creatinine &lt; 1.5 x ULN Effective contraception , male female patient , risk conception exist Provision write informed consent analysis biological marker ( registration ) Prior therapy Thymosin alpha1 Prior chemotherapy relapse and/or metastatic NSCLC . Neoadjuvant/adjuvant chemotherapy permit least 12 month elapse end chemotherapy randomisation Prior treatment Epidermal Growth Factor Receptor target small molecule antibody Radiotherapy within 14 day prior drug administration , except follow : Palliative radiation organ chest may allow 2 week prior drug administration , Single dose palliative treatment symptomatic metastasis outside allowance discuss sponsor prior enrol Patients previously diagnose treat CNS metastases spinal cord compression may consider evidence clinically stable disease ( SD ) ( steroid therapy steroid dose taper ) least 28 day Patients toxicity come back ( least ) grade 1 Pregnancy suspect pregnancy Known severe hypersensitivity TKI product Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ Any evidence clinically active interstitial lung disease ( ILD ) ( patient chronic , stable , radiographic change asymptomatic patient uncomplicated progressive lymphangitic carcinomatosis need exclude ) As judge investigator , evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic renal disease ) As judge investigator , inflammatory change surface eye Evidence significant clinical disorder laboratory find make undesirable patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>EGFR Wild Type</keyword>
	<keyword>Thymosin Alpha 1</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Thymalfasin</keyword>
</DOC>